Working... Menu

Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00124969
Recruitment Status : Completed
First Posted : July 29, 2005
Last Update Posted : May 9, 2008
Information provided by:
Charite University, Berlin, Germany

Brief Summary:

Patients with end-stage renal failure have a markedly higher mortality because of cardiovascular events in comparison with the normal population. Disorders in the calcium metabolism, such as calcification of the vessel walls, occur very frequently. There are indications that calcium channel blockers are capable of lowering the cardiovascular mortality in patients with end-stage renal failure.

It is intended to carry out a prospective, randomized, double-blind, placebo-controlled, multicenter study in order to find out if the calcium channel blocker amlodipine is able to reduce the mortality of patients with end-stage renal failure.

The investigation will be carried out after suitable explanation and written informed consent in 356 patients aged between 18 and 90 years with end-stage renal failure and chronic haemodialysis treatment. The patients will be randomized to either treatment with amlodipine 10 mg/day or placebo. The occurrence of events will be documented and evaluated prospectively over a period of 30 months.

Condition or disease Intervention/treatment Phase
Kidney Failure, Chronic Drug: Amlodipine Drug: Placebo Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 356 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])
Study Start Date : January 2002
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Failure

Arm Intervention/treatment
Active Comparator: 1
Drug: Amlodipine
Other Name: Placebo

Placebo Comparator: 2
Drug: Placebo

Primary Outcome Measures :
  1. The primary outcome will be the survival rate. The secondary outcome will be cardiovascular events. [ Time Frame: Prospective: look forward using periodic observations collected predominantly following subject enrollment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • End-stage renal disease
  • Hemodialysis
  • Hypertension
  • Written informed consent

Exclusion Criteria:

  • Hypotension of less than 90 mmHg systolic
  • High-grade aortic stenosis
  • Heart failure of NYHA stage III and IV
  • Acute myocardial infarction (within the last 4 weeks)
  • Acute heart failure
  • Known allergy to the medicament amlodipine or other constituents of the medicament
  • Severe disorders of liver function
  • Pregnancy and breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00124969

Layout table for location information
Charite Campus Benjamin Franklin
Berlin, Germany, 12200
Sponsors and Collaborators
Charite University, Berlin, Germany
Layout table for investigator information
Principal Investigator: Martin Tepel, Dr Charite Campus Benjamin Franklin

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00124969     History of Changes
Other Study ID Numbers: ADAM
First Posted: July 29, 2005    Key Record Dates
Last Update Posted: May 9, 2008
Last Verified: October 2006

Keywords provided by Charite University, Berlin, Germany:
End-stage renal disease, hemodialysis

Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents